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ABSTRACT 
Bone marrow derived mesenchymal stem cells (MSCs) demonstrate promise for 
musculoskeletal regenerative medicine.  An alternate approach to the direct delivery of 
stem cells is to exploit the concept of in situ tissue engineering. Biologics such as bone 
marrow aspirate concentrate and platelet rich plasma (PRP) enhance recovery from 
musculoskeletal injuries. These biologics contain growth factors which could act as 
chemoattractants for stem cells. In this project, we observed the migratory capacity of 
stem cells in response to biologics using of a microfluidics device.  The purpose of 
this study was to identify the optimal biologic for recruitment of stem cells.  Our 
hypothesis was that PRP would result in the greatest migration of MSC’s because of 
the milieu and concentration of growth factors contained in PRP.  We found that all 
biologics tested resulted in an increase in migration of stem cells compared to the 
control.  This demonstrates that biologics can be used as chemotactic agents to recruit 
MSCs to a site of injury. This information will reduce the need and therefore the risks 
and costs associated with direct stem cell delivery. 
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CHAPTER 1 
BACKGROUND 
Deficits in Natural Healing 
The body’s response to injury involves three major steps; inflammation, 
proliferation and remodeling [44].  After an injury, cellular and molecular signals 
stimulate the inflammatory response.  This results in the recruitment of neutrophils 
and macrophages.  The inflammatory stage of repair is responsible for fighting 
infection, clearing debris, and release of cytokines that stimulate angiogenesis and 
recruitment of mesenchymal cells [42].  After the inflammatory stage, proliferation of 
tissue and remodeling occur resulting in formation of native tissue. 
In several tissue types, the body is not able to respond appropriately after an 
injury.  This often results in insufficient rejuvenation of tissue.  For example, cartilage 
does not have its own blood supply and is instead supplied with nutrients by diffusion 
through synovial fluid [20].  Since cartilage lacks a blood supply, neutrophils and 
macrophages are not delivered after an injury and inflammation cannot occur.  Thus, 
cartilage has a limited regenerative capacity.  Treatments for musculoskeletal injuries 
should be aimed at supplementing the body’s inadequate response to injury, thereby 
reducing pain, increasing functionality, and minimizing the extent of tissue 
deterioration. 
In situ Tissue Engineering 
The concept of in situ tissue engineering is to use regenerative therapies to 
create an environment that exploits the body’s natural healing ability.  This idea was 
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popularized by Chang Lee and Jeremy Mao using a rabbit model [24].  In this model, 
the articular surface of the humeral head was removed and replaced with a control 
scaffold or one infused with transforming growth factor β3 (TGF-β3).  Rabbits treated 
with a scaffold infused with TGF-β3 regained more weight bearing function and 
locomotion than controls.  The articular surface of TGF-β3 treated rabbits was 
regenerated by homing of endogenous cells, whereas the controls only had isolated 
areas of cartilage formation. This study demonstrated the potential of a 
chemoattractant to promote recruitment of local tissue cells and regional stem cells to 
the site of injury and promote tissue repair.  
 This exemplifies the potential of in situ tissue engineering for use in 
musculoskeletal regenerative therapies.  Though this model resulted in successful 
regeneration of the humeral head, use of concentrated TGF- β3 is not a clinical reality. 
TGF- β3 results in fibrosis, extracellular matrix proliferation and increased chemotaxis 
of inflammatory leukocytes [13]. The purpose of in situ tissue engineering should be 
to create this same healing environment without subjecting the body to the detrimental 
effects of cytokines such as concentrated TGF- β3. 
Current Therapies in Cartilage Repair 
Cartilage injuries have commonly been treated medically using intra-articular 
drugs.  These therapies do not address the causative underlying lesions and do not 
supplement the natural healing process.  Glucocorticoids provide temporary relief for 
joint pain, but are palliative rather than therapeutic [23].  Hyaluronic acid injections 
are also used to treat arthritic joints.  The goal of this therapy is to restore the 
viscoelastic properties of the joint to enable normal joint mechanics [23].  Though this 
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therapy is frequently used, clinical trials indicate that hyaluronic acid therapy has 
minimal efficacy compared to placebo treatment [31].    
Chondral or osteochondral defects do not repair spontaneously or with medical 
treatment; therefore surgical intervention can be necessary to preserve the joint.  The 
ultimate goal of a surgical procedure, such as microfracture, is to provide the joint 
with an improved environment for restoration of hyaline cartilage.  Microfracture is a 
procedure that creates a break in the area of cartilage loss through the subchondral 
bone plate into the bone marrow.  Released marrow creates a clot that is enriched in 
stem cells for cartilage regeneration [27, 38].  Microfracture results in improvement in 
both pain and function compared to the pre-operative state of the patient [4].   
Microfracture tries to emulate in situ tissue engineering, but falls short.  The 
clot results in formation of fibrocartilage, which is inferior to native hyaline articular 
cartilage because it has different biological, structural and mechanical properties [20].  
Microfracture causes detrimental changes such as thickening of subchondral bone, and 
formation of cysts and intra-lesional osteophytes in one third of patients [18].  
Additionally, the fibrocartilage does not interdigitate with surrounding tissue, resulting 
in an area that is weaker and more prone to re-injury [27].   
Neither surgical nor non-surgical interventions have been sufficient to restore 
normal viability to the articular cartilage surface.  Both treatment modalities have 
drawbacks that have yet to be overcome.  Ultimately, regenerative therapies should be 
considered in place of, or to supplement the use of commonly used treatments.  
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Mesenchymal Stem Cells 
Mesenchymal stem cells can be used to enhance musculoskeletal repair after 
injury.  Mesenchymal stem cells (MSCs) proliferate extensively in vitro and 
differentiate into varying tissues of mesenchymal origin, such as chondrocytes, 
tenocytes, adipocytes, or osteoblasts [7].  Autogenous bone marrow or adipose 
mesenchymal stem cells are culturally expanded and then reintroduced into the injured 
patient [15].  This process has realized success both clinically and experimentally.  
In one study, seventy-two matched human patients were treated with either 
autologous chondrocyte implantations (ACI) or bone marrow derived MSCs.  Patients 
treated with MSCs had improved quality of health and sport activity that was 
comparable with patients treated with ACI [29].  This indicates that MSC treatment is 
preferential to ACI therapy because it achieves comparable results and does not have 
potential negative side effects such as cartilage donor site morbidity.  Autologous bone 
marrow MSCs have been culture expanded and applied to cartilage defects of 
osteoarthritic knees of twelve human patients [43].  Patients who received the cell 
transplant had improved formation of hyaline cartilage and higher arthroscopy scores 
than control, untreated patients.  Histological observations were made in an in vivo 
study using a rabbit model [45]. Full-thickness cartilage defects of the knee were 
treated with MSC or autologous chondrocyte implantation.  In comparison to defects 
treated with autologous chondrocyte transplantation, MSC-treated defects showed 
more complete integration with surrounding cartilage, more normal architecture and 
presence of a tidemark.  
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MSCs have also been successfully used to increase healing capacity in 
tendons.  Using horses as a model, culturally expanded mesenchymal stem cells were 
injected into collagenase-induced tendinopathies.  Increased repair and organization of 
tissue was observed in comparison to scar tissue formation in control limbs [9].  In a 
case-based twelve month trial, bone marrow mononuclear cells were isolated and 
administered at the time of surgery in rotator cuff repair of fourteen human patients 
[17]. All but one of the patients showed increased functional status of the rotator cuff.  
This study supports the use of MSCs in tendinopathies in humans. 
Though the full potential of MSC therapy has yet to be fully understood, some 
studies indicate that it is not risk-free.  MSC derived chondrocytes implanted into 
muscle express hypertrophy genes that lead to cell death, calcification and 
vascularization, but articular-derived chondrocytes are stable after implantation into 
muscle [2].  This indicates that MSC derived chondrocytes are prone to alternations 
that would not occur with native articular cartilage.  Additionally, MSCs can undergo 
spontaneous differentiation in culture.  This is rare and can be controlled in vitro, but 
controlling differentiation in vivo might be more difficult [22].  
MSC therapy is also time-consuming.  It requires extracting bone marrow and 
then allowing the stem cells to proliferate.  This process can take up to six weeks, at 
which point an acute injury will have had time to deteriorate [15].  One solution to this 
problem would be the use of allogeneic stem cells.  Research has suggested that MSCs 
are immune-privileged; meaning that they can mediate suppression of T-cell 
proliferation and can be transferred into mismatched haplotype patients [1].  However, 
recent reports refute the hypothesis that MSCs are immune-privileged.  Autologous 
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stem cells implanted into infarcted hearts have sustained benefits on heart function, 
but allogeneic stem cells are unable to preserve heart function long-term [21].  
Differentiation of allogeneic cells results in a switch from immune-privileged to 
immune-reactive, rendering them susceptible to humoral and cell-mediated 
cytotoxicity.  
MSC characteristics also vary based on several factors.  The ability of MSCs to 
differentiate and replicate could be altered depending on where they are isolated from, 
age of the individual, and growth conditions in tissue culture.  Bone marrow derived 
MSCs from older donors have decreased proliferative capacity and chondrogenic 
differentiation capacity opposed to MSCs from young donors [32].  In comparison to 
adipose and skeletal muscle stem cells, bone marrow derived MSCs have superior 
proliferative capacity, chondrogeneic capacity and osteogenesis [34].  Although 
synoviocyte derived MSCs have greater proliferative capacity and chondrogenesis 
than bone marrow derived cells, they are less accessible than bone marrow MSCs.  
Therefore, bone marrow MSCs are more widely used [22].   
An additional confounding factor for MSC therapy is that it lacks FDA 
approval.  To use MSCs regularly as a therapy for musculoskeletal injuries in humans, 
more time is needed for regulatory approval.  Since there are so many variables that 
can affect stem cells and confound their use, alternate options for treatment of 
musculoskeletal injuries should be considered.   
Biologics 
A novel approach to in situ tissue engineering is the use of biologics to create a 
regenerative environment in tissues that lack their own healing capacity.  A biologic is 
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a medicinal agent that is produced by the body rather than artificially synthesized. 
Biologics contain bioactive growth factors such as TGF-β1 and TGF-β3 and platelet-
derived growth factor (PDGF) [13].  As demonstrated by Mao’s rabbit model, TGF-β3 
is a chemoattractant for cells [24].  Similarly, PDGF acts a chemoattractant for cells of 
mesenchymal origin [35].  Since biologics contain growth factors that can act as 
chemoattractants, it follows that they could be used to modulate the local tissue 
environment and promote migration of healthy cells to a site of injury.  Platelet rich 
plasma, bone marrow aspirate and bone marrow aspirate concentrate are biologics that 
have all been used to this end.  
Platelet rich plasma (PRP) is produced through blood aspiration followed by 
centrifugation.  This results in a product that contains all the components of blood, 
though in different concentrations [6].  According to the Red Cross, PRP must contain 
at least 200,000 platelets/μl.  There are no standards for the other components of PRP 
which include leukocytes, various proteins and hormones, and erythrocytes.  Bone 
marrow aspirate (BMA) is collected through the use of a bone marrow biopsy needle 
and no further processing is necessary [36].  Bone marrow aspirate concentrate 
(BMAC) is prepared through aspiration of bone marrow followed by density gradient 
centrifugation [14, 38].   
Bone Marrow Aspirate  
Treatment of meniscal tears with BMA in sheep resulted in improved 
vascularization and integration of the repair site [11].  In an in vitro study using 
suspensory ligament cells, acellular bone marrow aspirate was subjected to a freeze-
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thaw cycle to render the aspirate acellular.  This aspirate was more successful than 
PRP at promoting anabolic responses of the ligament matrix [36]. 
Bone Marrow Aspirate Concentrate  
A prospective study in human patients examined the use of BMAC in a 
collagen matrix for cartilage defects [16].  The results revealed improved clinical 
scores and the formation of hyaline-like cartilage.  However, this study was performed 
on 15 people, out of which, only four underwent second-look arthroscopy, and there 
were no controls.  Using an equine model, use of BMAC in conjunction with 
microfracture resulted in significantly more improvement of full thickness cartilage 
defects compared with microfracture alone [14].  
Platelet Rich Plasma 
A controlled study comparing platelet rich plasma to hyaluronic acid injections 
in patients with chronic knee pain showed that PRP treatment significantly reduced 
pain in comparison to hyaluronic acid [23].  Closer examination revealed that the 
difference was only significant in patients younger than 50 that had only moderate 
degenerative changes.  Administration of PRP also resulted in increased improvements 
in patients with epicondylitis compared with corticosteroid injections [19].  Patients 
treated with PRP showed continued improvement over a two year period but those 
treated with corticosteroids returned to baseline.  This is in opposition with another 
study that showed the positive effects of PRP treatment were not long-lived in chronic 
knee degeneration [12].  PRP use for musculoskeletal injuries has varying degrees of 
success and longevity.  This could ensue from individual differences such as age or 
severity of disease, though it is also possible that differences in the use of PRP play a 
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role in the effectiveness of the treatment.  The amount of PRP used, whether or not a 
scaffold was present, if PRP was activated or not and which commercial system was 
used to make PRP could all play a role in affecting the outcome of studies examining 
the effects of PRP on tissue regeneration [26].  
Though the general protocol for making PRP is consistent, the commercial 
production systems vary tremendously.  Differences include the number of 
centrifugations, duration of centrifugation and original blood volume.  The importance 
of this is that different systems result in formation of PRPs with different 
compositions of platelets and leukocytes [26].  More platelets are not necessarily 
better.  The optimal range of platelet concentration for bone regeneration in the rabbit 
is 3.8*10^5 - 1.8*10^6 platelets/μl [43].  A lower concentration has no effect on 
regeneration and a higher concentration appears to have an inhibitory effect on 
regeneration.  Commercial PRP systems increase platelet concentrations from 1.5 to 8 
times the original concentration in venous blood [26].   
The effect of leukocyte concentration on healing is questionable. The presence 
of neutrophils can be detrimental to tissue, as they release reactive oxygen species 
during the inflammatory stage of healing [40].  However, the presence of leukocytes 
during repair helps to remove debris, protect from infection, promote angiogenesis, 
and activate growth factors [3].  It is unclear if leukocyte high PRP would be 
beneficial or detrimental to the tissue.  In a comparison of leukocyte low and 
leukocyte high PRP, an increased inflammatory response was seen five days after 
application in rabbits that received leukocyte high PRP [10].  However, no differences 
were noted on day fourteen.  The lack of standards for use of PRP and lack of 
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understanding of the healing process makes it difficult to fully assess the effectiveness 
of this treatment.  This highlights the importance of monitoring the composition of 
PRP to help determine its functionality.  
Thesis 
In situ tissue engineering strives to create an optimal environment for 
regeneration of tissues.  This concept has been pursued through use of surgical 
procedures such as microfracture, cell delivery, and delivery of autologous biologic 
substances.  Though stem cell therapy is very promising for in situ tissue engineering, 
it is costly, time-consuming and lacks FDA approval.  This makes it necessary to seek 
other options.  Exploiting biologics a source for regenerative medicine is an alternative 
to direct stem cell delivery. 
 Biologics contain growth factors that have the ability to modulate the 
environment and induce migration of cells.  While studying the individual effects of 
growth factors and other biological components such as leukocytes is informative, it 
does not tell us how the body will respond to the milieu of factors within a biologic.  It 
is still unclear if one of the studied biologics provides more benefit than others.   
In the experiments of this thesis, a microfluidics device was used to measure 
the direct competition of chemoattraction between biologics.  The goal for this study 
was to determine which biologic was capable of causing the greatest migration of stem 
cells and would therefore be the optimal biologic for use in regenerative medicine.  
The hypothesis was that all the biologics would attract stem cells but leukocyte low 
platelet rich plasma (L
lo
PRP) would be the optimal biologic because of the diminished 
concentration of inflammatory cytokines compared to the other biologics.   
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CHAPTER 2 
MESENCHYMAL STEM CELL MIGRATION 
Methods 
All experiments were completed at Cornell University, College of Veterinary 
Medicine. Animal use was approved by the Institutional Animal Care and Use 
Committee. 
Mesenchymal Stem Cell Isolation  
  Bone marrow aspirate was collected from eight mature horses aged 2-19 years.  
Horses were either euthanized or sedated, and the sternum was clipped and scrubbed.   
Lidocaine anesthesia was administered to horses that were sedated.  Bone marrow was 
drawn using a Jamshidi needle and a syringe containing 10mls of 5000 units/ml acid 
citrate dextrose.  The aspirate was diluted 1:1 with sterile phosphate buffered saline 
(PBS), and layered on top of Ficoll (GE Healthcare, Piscataway, NJ) in a 50ml conical 
tube at a ratio of 3:2, respectively.  Conical tubes were centrifuged at 400g and 4°C for 
20 minutes.  The mononuclear cell fraction was retained and rinsed with PBS, and 
centrifuged again at 500g, 4°C for 5 minutes.  This was repeated and the final cell 
pellet was resuspended in MSC media (Dulbucco’s Modified Essential Medium, 10% 
FBS, penicillin and streptomycin, hepes, L-glutamine, bFGF).  Cells were expanded in 
tissue culture plates at 37°C in a humid, 5% CO2/air incubator.  Cells were washed 
and medium was changed every third day until they reached 80-90% confluence. Cells 
were then lifted with Accumax (EMD Millipore Corporation, Billerica, MA) and 
cryopreserved in complete media with 10% DMSO until needed.      
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Bone marrow aspirate/ Bone marrow aspirate concentrate (BMAC) 
  Bone marrow was aspirated as described above.  BMA was additionally 
processed using SmartPReP 2 technology (Harvest Technology Corp, Plymouth, MA) 
to generate BMAC.  Samples were aliquoted into 1ml cryovials and frozen at -80°C.  
Prior to freezing, complete blood counts for both BMA and BMAC were performed 
by Cornell University Hospital for Animals. 
Platelet rich plasma 
  Horses were sedated and the jugular vein was clipped and scrubbed.  50mls of 
blood were drawn using an 18 gauge 1.5 inch needle into a syringe with 10mls of 5000 
units/ml acid citrate dextrose.  Leukocyte low PRP (L
lo
PRP) was generated from 
blood using the Double Syringe Autologous Conditioned Plasma System (Arthrex, 
Naples, FL).  Leukocyte high PRP (L
hi
PRP) was generated from blood using the GPS 
III Platelet Separation system (Biomet, Warsaw, IN).  Samples were aliquoted into 
1ml cryovials and frozen at -80°C.  Samples were retained for complete blood counts.  
Controls  
  Human recombinant platelet derived growth factor AB (PDGF-AB) (Life 
Technologies, Grand Island, NY) was used as the positive control to discriminate 
between poorly migrating cells and ineffective biologics [35].  PDGF-AB was 
reconstituted at a concentration of 5000ng/ml according to manufacturer instructions 
and stored in aliquots at -4°C.  MSC media with 10% FBS was used as the neutral 
control (NC).  Negative controls such as serum free media resulted in MSC death 
during the experiments.  
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Microfluidics preparation 
  MSCs were thawed and incubated in medium at 37°C in a humid, 5% CO2/air 
incubator the day prior to use.  To allow CO2 equilibration to prevent air bubble 
formation, the μ-slide chemotaxis device (Ibidi LLC, Verona, WI), 10% FBS media, 
and 1% FBS media were also incubated a day prior to use.   
  The following day, MSCs were washed with PBS, lifted using Accumax and 
centrifuged at 500g for 5 minutes.  The cell pellet was resuspended at an average 
concentration of 166 cells/cm
3 
in the 10% FBS media that was equilibrated on the 
previous day.
 
 Caps were placed on ports C, D, E and F (Figure 1) and 6ul of cell 
suspension was dropped onto port B.  Gentle aspiration was applied to port A to pull 
cells into the observation area.  Caps were removed and the device was covered with a 
lid.  The device was placed in a petri dish with a wet paper towel and the dish was 
wrapped in parafilm and incubated for 2-3 hours to allow the MSCs to adhere.  
Biologics were thawed and centrifuged at 12,000g for 20 minutes to remove cell 
debris. The biologic supernatant and PDGF were incubated with the device to allow -
CO2 content to equilibrate.   
 
Figure 1: The u-slide chemotaxis device. The area between ports A and B is the 
observation area where the MSCs are seeded. The areas indicated in dark gray are the 
reservoir wells where the putative chemoattractants are placed.  
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  After incubation, the reservoir wells of each device were filled with 60μl of 
1% FBS media.  Caps were placed on ports A, B, E and F and 10ul of PDGF or 
biologic was placed in port D and 5μl of 1% FBS media was aspirated from port C to 
draw the biologic into the reservoir well.  Caps were then moved to cover ports A, B, 
C and D and 10% FBS media was placed in port F and 5μl of 1% FBS media was 
aspirated from port E so that a direct competition of chemoattraction could be 
measured between a biologic and the NC. 
  The device was then imaged using live cell imaging on an inverted bright field 
microscope (Thorlabs, Newton, NJ) with a 4X objective (Olympus America Inc, 
Center Valley, PA) every five minutes for a period of twenty four hours. Time-lapse 
images were analyzed by tracking the migratory patterns of individual cells by use of a 
custom code written in Image J (NIH, Bethesda, MD). The program tracked the 
location of the computer cursor as it hovered over the cells for the duration of the 
time-lapse videos.  Cell (x, y) coordinates were recorded for every frame.  Cells were 
tracked up to the point of division, death, migration out of the center well, or 24 hours 
of migration.  A custom code written in Matlab (MathWorks Inc, Natick, MA) was 
used to compile the (x, y) coordinates and determine displacement of each cell from its 
location at time 0 to the final location at time 24 hours. The program averaged 
displacement of individual cells towards the biologic or NC to give an overall 
displacement for each experiment.  The number of cells migrating in each direction 
was also recorded.  Cell flux (%migrated * µm/24hrs) was calculated to represent the 
rate of movement of MSCs within the device.   
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  The percentage of cells migrated was used as a measure of the ability of 
biologics to act as chemotaxis agents for MSCs.  Chemotaxis refers to the ability to 
cause a directed migration of cells [5].  Cells influenced by a chemotactic factor will 
move along a chemical gradient instead of randomly (Figure 2).  Displacement of 
MSCs was used as a measure of the ability of a biologic to stimulate chemokinesis.  
Chemokinesis refers to the ability to cause an increase in rate of migration [5].  Cells 
influenced by a chemokinetic factor will move further in the same amount of time as 
cells that were not influenced by the chemokinetic factor, but not in any specific 
direction.   
 
Figure 2: Chemotaxis versus chemokinesis. Black lines indicate cell trajectories. A) 
Cells are not influenced by any factors, they move randomly. B) Cells are influenced 
by a chemokinetic factor.  They have increased the rate of migration, but do not move 
in a particular direction. C) Cells are influenced by a chemotactic factor. They have 
not increased the rate of migration, but directed migration is occurring either up or 
down a chemical gradient.  
 
  Displacement and percentage of cells migrating toward a putative 
chemoattractant or NC are useful measures since they relate directly to chemokinesis 
and chemotaxis, respectively.  However, these variables fail to give a comprehensive 
picture of cell migration, therefore cell flux was calculated.  Cell flux is a 
measurement of the rate of flow of the cells.  It indicates overall migration of a cell 
population toward either a putative chemoattractant or a control substance.  
A                                   B                 C 
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Statistics  
Outcome variables included the number of cells migrated, cell displacement 
and cell flux.  The number of cells that migrated was normalized by calculating the 
percentage migrated in order to control for differences in seeding density of the MSCs 
between experiments.  The NCs were compared using a Kruskal-Wallis one-way 
ANOVA by ranks using JMP Pro 11 (SAS Institute Inc, Cary, NC).  Independent 
variables were NC, PDGF, BMA, BMAC, L
lo
PRP and L
hi
PRP.  Independent variables 
were analyzed by using a Kruskal-Wallis one-way ANOVA by ranks.  A p-value of < 
0.05 was considered significant.  Post hoc comparisons between independent variables 
were made using the Wilcoxon rank-sum test with a downward adjustment in the p-
value to compensate for the increased chance of type-I error with multiple 
comparisons.  A p-value of < 0.01 was considered significant. 
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Results  
Visual interpretation of time-lapse videos indicated that cells tended to migrate 
toward biologics in preference to NC (Figure 3). 
   
Figure 3: Cell migration images. Image on the left is the μ- slide chemotaxis device 
immediately after preparation. Image on the left is the μ-slide chemotaxis device after 
completion of the experiment. The observation area is the area between the thick black 
lines. The putative chemoattractant is on the left side of the observation area.  Putative 
chemoattractant in this experiment was leukocyte high platelet rich plasma (L
hi
PRP).  
The NC is on the right side of the observation area.  
 
Every experimental set up on the μ-slide chemotaxis device allowed for direct 
competition of a putative chemoattractant against the NC.  Since each set up contained 
a NC, at the end of the trial five NC groups existed.  NC outcome variables from each 
experiment were compared (Table 1).  NCs were not significantly different from each 
other, so NC data was averaged for further statistical analyses.   
Table 1 – Percentage of cells migrated, displacement and cell flux toward NC. 
Putative chemoattractant in each experiment is indicated; PDGF – platelet derived 
growth factor, BMA – bone marrow aspirate, BMAC – bone marrow aspirate 
concentrate, L
lo
PRP – leukocyte low platelet rich plasma, LhiPRP – leukocyte high 
platelet rich plasma. Significance was determined with a Kruskal-Wallis one way 
ANOVA.  A p-value < 0.05 was considered significant.  
 
 PDGF BMA BMAC L
lo
PRP L
hi
PRP Average p-value 
Percent migrated 28.61 22.63 26.13 23.40 17.84   23.72 0.24 
Displacement (μm) 44.83 40.15 31.47 24.59 27.49 33.71 0.15 
Cell flux 55.01 36.84 36.99 28.49 21.34 35.73 0.10 
L
hi
PRP   L
hi
PRP   Observation area Observation area NC   NC   
Time 0 hours Time 24 hours 
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All biologics attracted a greater percentage of cells compared to the NC 
(Figure 4A; p < 0.001).  PDGF also attracted a greater percentage of cells compared to 
the NC (p < 0.001). None of the biologics were different from each other. Biologics 
and PDGF recruited three times more cells compared to the NC group.   
BMAC stimulated significantly more displacement than L
lo
PRP (Figure 4B, 
p=0.005). Similarly, PDGF stimulated significantly more displacement than L
lo
PRP, 
(p = 0.002).  None of the other biologics were significantly different from each other.  
BMAC displacement was not significantly different from BMA or L
hi
PRP.  None of 
the biologics resulted in a significantly different displacement from the NC.  
Displacement of cells toward PDGF was significantly greater than toward the NC (p = 
0.01).   
Cell flux was greater toward BMAC than all of the other biologics, but only 
significant with respect to L
lo
PRP (Figure 4C, p = 0.002).  Cell flux toward L
hi
PRP 
was also significantly greater than toward L
lo
PRP (p = 0.01). L
hi
PRP resulted in 1.8 
times more cell flux compared to L
lo
PRP.  L
hi
PRP resulted in greater cell flux than the 
NC (p = 0.001).  BMAC also resulted in greater cell flux than the NC (p = 0.0009).  
L
lo
PRP resulted in significantly less cell flux than the NC (p = 0.01).  Cell flux toward 
PDGF was significantly greater than the cell flux toward the NC (p = 0.0009).  PDGF 
resulted in more cell flux than L
lo
PRP (p = 0.002).   
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Figure 4: Percentage of cells that migrated (A).  Displacement of cells (B).  Cell flux 
(C).  Data are represented as median with maximum and minimum values, n=8.  NC = 
neutral control, PDGF = platelet derived growth factor, BMA = bone marrow aspirate, 
BMAC = bone marrow aspirate concentrate, L
lo
PRP = leukocyte low platelet rich 
plasma, L
hi
PRP = leukocyte high platelet rich plasma.  Bars indicate significant 
differences between groups. Significance was determined by a Kruskal-Wallis 
followed by Wilcoxon multiple comparison post-hoc test.  A p-value < 0.01 was 
considered significant.   
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CHAPTER 3 
DISCUSSION AND CONCLUSION 
Discussion 
The results from this study did not support the hypothesis that L
lo
PRP would 
cause the most migration of mesenchymal stem cells in comparison to other biologics.  
Each biologic tested contains a unique milieu of growth factors.  We proposed that 
L
lo
PRP would cause the most migration because of its milieu of bioactive growth 
factors.    
Contrary to our hypothesis, the results showed that BMAC and L
hi
PRP resulted 
in more migration than L
lo
PRP.  Though these two biologics were not significantly 
different from each other, BMAC resulted in a greater overall flux than L
hi
PRP.  From 
this experiment, it appears that BMAC results in greater chemokinesis, while L
hi
PRP 
resulted in slightly more chemotaxis.  Since flux incorporates both of these values, 
there was no significant difference between BMAC and L
hi
PRP.  Though L
lo
PRP did 
not result in more cell flux or displacement than other biologics, it has the ability to 
cause chemotaxis of MSCs, as seen by the percentage of migrated cells.   
Both chemotaxis and chemokinesis factors are important in determining the 
optimal biologic for enhanced stem cell recruitment.  The optimal biologic would be 
able to cause directed migration of cells towards the wound and increase the speed at 
which cells could reach the wound.  Growth factors range in their ability to stimulate 
chemotaxis and chemokinesis.  For instance, C-X-C motif chemokine 12 (CXCL12) 
can promote chemotaxis but not chemokinesis in human blood cord stem cells [30].  
Insulin-like growth factor (IGF) I and II can promote chemotaxis and chemokinesis of 
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malignant mesothelioma cells [25].  PDGF is a known chemotactic growth factor for 
cells of mesenchymal origin [35].  Growth factor interactions can also alter the 
response of a cell.  For instance, PDGF results in an increased expression of IGF-I 
receptors [33].  
All biologics used in this study would contain comparable levels of IGF-I, 
because of the basal level of IGF-I in blood and bone marrow [39].  The differences in 
concentrations of PDGF and other growth factors in the biologics was likely the cause 
of the varying responses seen by MSCs exposed to biologics.  The percentage of cells 
migrated toward L
lo
PRP was just as great as any of the other biologics.  However, it 
induced the least amount of cell displacement.  Another way that this can be stated is 
that the chemotactic ability of L
lo
PRP was equivalent to the other biologics studied, 
but it had an inferior ability to cause chemokinesis.   
Cell flux is a particularly useful measure of migration because it represents 
both chemotactic and chemokinetic capability of biologics.  Since L
lo
PRP stimulated 
the least cell flux of any of the biologics it can be presumed that L
lo
PRP is not the 
optimal biologic for in vivo use.  BMAC and L
hi
PRP stimulated more cell flux than 
L
lo
PRP.  Therefore it is suggested to further explore their potential use in vivo and to 
determine if either have greater potential for musculoskeletal regeneration.  
Conclusion 
One aspect of cell migration that was not measured in this study was the effect 
of the biologics on cell division.  Growth factors not only cause cell movement, but 
also have mitogenic effects on cells.  The mitogenic capability of a biologic could 
have an effect on cell flux.  When a cell divides, it produces two daughter cells.  If 
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both cells migrated toward the chemoattractant, then the percentage of cells migrated 
would change and cell flux would increase for that direction.  Unfortunately, the 
program that was used to manually track the cells in these studies was limited in this 
regard.  It was not possible to start tracking part-way through the time-lapse video.  
This would have been necessary if daughter cells were tracked in order to prevent 
tracking a parent cell twice.  An additional confounding factor for tracking daughter 
cells was the rate of division.  In many instances, the daughter cells also divided.  One 
way to overcome this would be to inhibit division of MSCs through irradiation and 
determine if the flux changes.   
In this experiment cells could only be tracked for twenty-four hours.  After 
twenty-four hours, MSCs became too confluent to reliably track individual cell 
movements.  If cells were plated at a lower concentration to allow for longer 
observation, they did not migrate until they became more confluent.  This suggests 
that cell-cell interactions are necessary to promote migration.  This is consistent with 
studies that showed that cells at lower seeding densities were less capable of 
differentiation, indicating that cell-cell interactions are important for MSC function 
[28].  
Interesting phenotypes were observed in early experiments that were allowed 
to run for longer periods of time.  Cells exposed to BMA or BMAC tended to roll up 
into long sheets of cells and then conglomerate into spheroids.  Some studies have 
deliberately induced spheroid formation [8].  This can occur when cells become 
confluent or are nutrient deprived.  Formation of spheroids allows stem cells to 
maintain viability in serum-free or hypoxic conditions.  This is consistent with the 
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present study, as the cells that reached confluence were imaged for three or more days.  
Cells exposed to PRP tended to exhibit a streaming behavior that appeared to be 
similar to behavior shown by fungal hyphae.  The reason for this is unknown.   
The next step in this experiment should be to determine if the findings of this 
study are consistent in vivo.  Specifically, it should be ascertained if either BMAC or 
L
hi
PRP is superior in vivo.  One difficulty in finding this out is that there are minimal 
standards for processing consistent biologics.  This is something that will need to be 
specified if biologics are used regularly in musculoskeletal injuries.  Additionally, a 
mechanism for tracking endogenous MSC migration in vivo has yet to be determined.      
Another direction that this project could take would be to study the response of 
other cell types to the same biologics that the MSCs were exposed to.  It is worthwhile 
to find out if chemotaxis and chemokinesis of cell types that compose musculoskeletal 
tissues could be promoted by biologics.  Results from an initial trial on chondrocytes 
suggest that BMA is capable of stimulating migration; the other biologics only had a 
minimal effect on chondrocyte migration.   
  In conclusion, we found that L
lo
PRP, L
hi
PRP, BMA and BMAC all result in 
chemotaxis and/or chemokinesis of MSCs.  Specifically, BMAC and L
hi
PRP result in 
significantly more cell migration than L
lo
PRP.  Biologics can be used as chemotactic 
agents to recruit MSCs to a site of injury. This information has the potential to reduce 
the need and therefore the risks and costs associated with direct stem cell delivery.
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